The analysis of meconium for cocaine and metabolites has proved to be a reliable method for the detection of fetal cocaine exposure. Better sensitivity and a larger gestational window of detection have been demonstrated for meconium testing as compared with neonatal urine testing. Cocaine and cocaine metabolites, including benzoylecgonine, ecgonine methyl ester, cocaethylene, norcocaine, benzoylnorecgonine, and m-hydroxybenzoylecgonine, have been identified in meconium. The origin of these metabolites, whether maternal or fetal, has not been established. This study was conducted to compare the disposition of cocaine and metabolites in meconium from fetuses exposed to cocaine with that of urine from cocaine abusers. Meconium specimens were obtained from six neonates of mothers positive for cocaine use by urinalysis or self-reporting or both during pregnancy. Urine specimens were obtained from 17 adult female and 17 adult male cocaine users enrolled in a treatment program. Specimens were analyzed by gas chromatography-mass spectrometry for cocaine and 12 related analytes. The following analytes were identified and measured in meconium and urine: anhydroecgonine methyl ester; ecgonine methyl ester; ecgonine ethyl ester; cocaine; cocaethylene; benzoylecgonine; norcocaine; norcocaethylene; benzoylnorecgonine; m-and p-hydroxycocaine; and m-and p-hydroxybenzoylecgonine. In addition, both m-and p-hydroxybenzoylecgonine were found to exhibit approximately equal cross-reactivity with benzoylecgonine in the EMIT and TDx assays. The presence of p-hydroxybenzoylecgonine in meconium suggested that this newly identified metabolite, like m-hydroxybenzoylecgonine, might serve as a valuable marker of fetal cocaine exposure during pregnancy. The presence of cocaine and anhydroecgonine methyl ester in meconium was attributed to transfer across the placenta from the mother. However, the origin of the hydrolytic and oxidative metabolites of cocaine could not be established because they were also identified in urine specimens of adult female cocaine users and could have arisen in meconium from either fetal or maternal metabolism.
Introduction
The analysis of meconium for cocaine and metabolites has proved to be a reliable method for the detection of fetal cocaine exposure. Better sensitivity and a larger gestational window of detection have been demonstrated for meconium testing as compared with neonatal urine testing. Cocaine and cocaine metabolites, including benzoylecgonine, ecgonine methyl ester, cocaethylene, norcocaine, benzoylnorecgonine, and m-hydroxybenzoylecgonine, have been identified in meconium. The origin of these metabolites, whether maternal or fetal, has not been established. This study was conducted to compare the disposition of cocaine and metabolites in meconium from fetuses exposed to cocaine with that of urine from cocaine abusers. Meconium specimens were obtained from six neonates of mothers positive for cocaine use by urinalysis or self-reporting or both during pregnancy. Urine specimens were obtained from 17 adult female and 17 adult male cocaine users enrolled in a treatment program. Specimens were analyzed by gas chromatography-mass spectrometry for cocaine and 12 related analytes. The following analytes were identified and measured in meconium and urine: anhydroecgonine methyl ester; ecgonine methyl ester; ecgonine ethyl ester; cocaine; cocaethylene; benzoylecgonine; norcocaine; norcocaethylene; benzoylnorecgonine; m-and p-hydroxycocaine; and m-and p-hydroxybenzoylecgonine. In addition, both m-and p-hydroxybenzoylecgonine were found to exhibit approximately equal cross-reactivity with benzoylecgonine in the EMIT and TDx assays. The presence of p-hydroxybenzoylecgonine in meconium suggested that this newly identified metabolite, like m-hydroxybenzoylecgonine, might serve as a valuable marker of fetal cocaine exposure during pregnancy. The presence of cocaine and anhydroecgonine methyl ester in meconium was attributed to transfer across the placenta from the mother. However, the origin of the hydrolytic and oxidative metabolites of cocaine could not be established because they were also identified in urine specimens of adult female cocaine users and could have arisen in meconium from either fetal or maternal metabolism.
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Illicit cocaine is commonly self-administered by the intravenous, smoked, and intranasal routes. Other drugs such as heroin, marijuana, methadone, and ethanol also may be consumed at the same time. The route of cocaine administration and the concurrent use of additional drugs can have a significant impact on the pharmacological outcome (1,2) and on the disposition of cocaine constituents in different biological fluids and tissues. The smoking route differs from the intravenous and intranasal routes by delivering a combination of cocaine and pyrolysis products to the user. The major pyrolysis product, anhydroecgonine methyl ester, formed during the heating of cocaine, has not been thoroughly investigated but was suggested to influence the overall cardiovascular toxicity of cocaine (3) . The coadministration of alcohol with cocaine results in the formation of cocaethylene (4, 5) , a cocaine analogue with similar pharmacological actions to cocaine but with an extended half-life (6) . After absorption, cocaine and cocaethylene undergo rapid biotransformations in adults through hydrolytic and oxidative pathways to numerous active and inactive metabolites including benzoylecgonine, ecgonine methyl ester, norcocaine, and benzoylnorecgonine (7) (8) (9) . Small amounts of arylhydroxy metabolites of cocaine, including rn-hydroxybenzoylecgonine and m-and p-hydroxycocaine, have also been identified in the urine of adult cocaine users (10, 11) . The metabolism and pyrolytic decomposition of cocaine are illustrated in Figure 1 .
The metabolite, m-hydroxybenzoylecgonine, was reported to be an important contributor to immunoreactivity in cocaine metabolite assays of meconium from infants exposed to drugs (12) . Recently, Lewis et al. (13) found that of 208 meconium specimens screened positive for cocaine metabolite, 161 (77.4%) specimens were confirmed positive for benzoylecgonine by gas chromatography-mass spectrometry (GC-MS), 132 (63.5%) were positive for cocaine, and 197 (94.7%) were positive for m-hydroxybenzoylecgonine. Forty-seven of the specimens were positive for m-hydroxybenzoylecgonine only. A second study by Lewis et al. (13) found m-hydroxybenzoylecgonine in 79% of meconium specimens examined Journal of Analytical Toxicology, Vol 20, October t996 (.IV = 58). Other cocaine metabolites and related analytes, including cocaethylene (14, 15) , ecgonine methyl ester (14) , norcocaine (16) , and benzoylnorecgonine (17) , have also been identified in meconium.
The origin of metabolites such as m-hydroxybenzoylecgonine in meconium specimens from infants exposed to cocaine is unclear. Lewis et al. (13) suggested that it is incorrect to assume that fetal cocaine metabolic pathways are identical to those found in the mother. Fetal enzymatic activities may differ from those in adults, and limited metabolism by one pathway could lead to more extensive metabolism by an alternate pathway (18) . Consequently, it is possible that m-hydroxybenzoylecgonine is selectively formed through fetal metabolism of cocaine to m-hydroxycocaine with subsequent hydrolysis or from oxidation of benzoylecgonine. An alternate pathway for the appearance of cocaine metabolites in meconium would be by transfer across the placental barrier from the mother. Selective sequestration of cocaine metabolites in meconium and in amniotic fluid could then occur from combinations of fetal hydrolytic and oxidative conversions, changes in solubility, ion trapping, and binding mechanisms, thereby preventing or retarding their clearance from the fetus.
This study was designed to investigate the disposition of cocaine metabolites in urine specimens from adult women and men who were heavy cocaine users and in meconium specimens collected from neonates exposed to cocaine in utero. Specimens were analyzed by GC-MS for cocaine, cocaine metabolites, and related analytes. A comparison of these profiles was made in an attempt to determine the origin of cocaine metabolites and related constituents in meconium.
Experimental

Chemicals, reagents, and materials
Cocaine 
Instrumentation
GC-MS analyses were performed on a Hewlett-Packard 5890A gas chromatograph fitted with a 7673A autosampler (Wilmington, DE). The gas chromatograph was interfaced with a Hewlett-Packard 5972 mass selective detector (MSD). A split-splitless capillary inlet system and an HP-1 fused-silica capillary column (12 m x 0.2-mm i.d., 0.33-gin film thickness) were used for analyses. The injection port and transfer line temperatures were 250~ and 295~ respectively. The initial oven temperature was held at 70~ for 1 rain, then programmed to 220~ at 35~ and then to 280~ at 30~
For each run, the electron multiplier voltage was initially set at tune parameters, followed by a 200-mV increase at 6.0 rain after injection.
Full scan mass spectral data were acquired over the range of 50-550 atomic mass units. Quantitation was performed with the MSD operating in the selected ion monitoring (SIM) mode. The mass-ion defect for the quantitation of each analyte was determined for each run. Ecgonine methyl ester, cocaine, cocaethylene, and benzoylecgonine were quantitated by comparisons of peak-area ratios for each analyte with those of the corresponding deuterated internal standard analogues. Anhydroecgonine methyl ester, ecgonine ethyl ester, norcocaine, norcocaethylene, benzoylnorecgonine, m-hydroxycocaine, m-hydroxybenzoylecgonine, p-hydroxycocaine, and p-hydroxybenzoylecgonine were quantitated by comparison of area ratios of each respective analyte with those of the nearest structurally related deuterated analogue. Prerun maintenance procedures included clipping the column and replacing the septum, liner, and injector seal. Apparent cross-reactivity measurements of cocaine analytes The assays were performed according to the manufacturers' recommended procedures. Standard drug concentrations were prepared in concentrations of 100, 1000, and 10,000 ng/mL. Cross-reactivity was determined as the ratio of apparent concentration (benzoylecgonine equivalents)/target x 100.
Collection of meconium specimens from infants exposed to cocaine
Meconium specimens were collected from neonates in neonatal intensive care units at Johns Hopkins Bayview Medical Center and University of Maryland Medical Systems as part of a study of prenatal cocaine exposure in low birth weight infants. Prenatal cocaine exposure was based on positive cocaine test results of maternal urine by EMIT (300 ng/mL) or positive maternal self-reported data of cocaine use during pregnancy. Meconium was obtained from the first or second postnatal defecation. Specimens were collected in polypropylene screw-cap jars and immediately stored at -30~
Collection of urine specimens from individuals in a cocaine treatment program
Urine specimens from adults using cocaine were collected as part of a 17-week clinical trial evaluating a behavioral intervention for treatment of cocaine use in individuals taking methadone. Participants were polydrug users enrolled in a methadone maintenance treatment program that included administration of daily methadone (50 rag) and weekly counseling. They qualified for the clinical trial by continuing to use cocaine during the first 5 weeks of methadone treatment. Data collected at admission from assessment instrumen and 17 women for GC-MS analysis. Demographic data for the selected subjects are listed in Table I .
Analysis of meconium and urine specimens by GC-MS
Frozen meconium specimens were allowed to thaw and were mixed. Specimens were then refrozen, and samples were weighed (0.1-0.7 g) in 150-x 16-ram disposable culture tubes. Internal standards (100 ng [2H3]-cocaine, [2H3]-ecgonine methyl ester, and [2H3]-benzoylecgonine and 50 ng [2H3]-cocaethylene) were added together with 2.0 mL methanol according to a published procedure for the analysis of cocaine and metabolites in meconium (19) . The contents were mixed with clean wooden applicators, and the tubes containing the applicators were vortex mixed. The wooden applicators were removed, and the suspensions were centrifuged at 2000 rpm for 5.0 rain. The supernatants were decanted into 100-x 13-mm glass culture tubes. A buffer (3 mL, 2M sodium acetate, pH 4) was added, and the tubes were vortex mixed, after which centrifugation at 2000 rpm for 5.0 min was performed. Super- natants were then decanted for analysis by SPE and GC-MS.
S t a n d a r d s
Meconium and urine specimens (0.001-0.1 mL) were analyzed by SPE and GC-MS according to a modified published procedure (20) for the simultaneous analysis of cocaine and metabolites. Briefly, specimens containing internal standards were treated with acetate buffer and added to conditioned SPE columns. The columns were washed, and the extracts were eluted with 6 mL methylene chloride-isopropanolconcentrated aqueous ammonium hydroxide (80:20:2, v/v/v). The organic phase was evaporated, and the residues were reconstituted in 0.02 mL acetonitrile. Extracts were treated with 0.02 mL BSTFA (1% TMCS) at 60~ for 30 min. GC-MS analysis was then performed.
Quantitative GC-MS analysis was performed by constructing duplicate nine-point standard curves containing known concentrations of each analyte in a drug-free meconium or urine matrix. The concentration ranges were 3-1000 ng/mL for cocaine, ecgonine methyl ester, and benzoylecgonine and 1.6-500 ng/mL for all other analytes. Duplicate control samples were prepared in each matrix containing 0, 100, and 500 ng/mL cocaine, ecgonine methyl ester, and benzoylecgonine and 0, 50, and 250 ng/mL of all other analytes. Calibration curves and control samples were analyzed with each specimen batch.
Statistical analysis
Cocaine and cocaine metabolite concentrations in adult men and women were compared with the Mann-Whitney U test, a nonparametric ranking test. Differences were considered significant ifp _< .05.
Results
GC-MS assay performance
Cocaine and analytes were assayed in meconium and urine by GC-MS using scan and SIM modes. The quantitative precision for each analyte was estimated from the analysis of control samples (N = 8) containing a standard concentration of each analyte in meconium (500 ng/g) and urine (400 ng/mL). Intraassay coefficients of variation were consistently less than 5%. Limits of detection (LOD) for cocaine analytes in meconium were determined by serial dilutions of known concentration of all analytes and were less than 7.5 ng/g. The LOD was established as the lowest concentration of each analyte that provided a signal-to-noise ratio greater than 5 for the quantitating ion, which had to be accompanied by the presence of two confirming ions. Qualifying ions were monitored visually and were required to be present for quantitation.
Identification of cocaine analytes in urine and meconium
Cocaine, cocaine metabolites, and related analytes were detected in varying amounts in urine specimens from adult cocaine users and in meconium specimens from infants exposed to cocaine (Figure 1 ). Each analyte was identified by comparison of retention times and mass spectral data of specimen extracts with those of authentic standards.
The mass spectra of the four hydroxy-metabolites, m-and p-hydroxycocaine and m-and p-hydroxybenzoylecgonine, extracted from urine are illustrated in Figure 2 . The hydroxyisomers displayed characteristic molecular ions at m/z 391 for m-and p-hydroxycocaine and m/z 449 for m-and p-hydroxybenzoylecgonine. The fragment ion at m/z 182, indicative of the loss of the derivatized hydroxybenzoic acid group, was present in the spectra of the hydroxycocaine isomers. The fragment ion at rn/z 193, indicative of the derivatized hydroxybenzoyl group, was present in all spectra of the isomers of hydroxycocaine and hydroxybenzoylecgonine. The fragment ion at m/z 240, indicative of the loss of the derivatized hydroxybenzoic acid group, was present in the spectra of the hydroxybenzoylecgonine isomers. Only partial resolution was achieved for the separation of m-hydroxybenzoylecgonine and p-hydroxycocaine (Figure 3) . Consequently, there was some overlap of these spectra as seen in Figure 2D , in which the fragment ion at m/z 240 from m-hydroxybenzoylecgonine appears in the spectra ofp-hydroxycocaine as a result of the unresolved components. Fortunately, unique ions could be selected for each analyte for use in quantitation by SIM. In addition, an unknown metabolite coeluted just before the appearance of derivatized m-hydroxyben- *Abbreviations: AEME = anhydroecgonine methyl ester: EME = ecgonine methyl ester; EEE = ecgonine ethyl ester: COC = cocaine; CE = cocaethylene; BZE = benzoylecgonine: NCOC = norcocaine: NCE = norcocaethylene; BNE = benzoylnorecgonine; m-HOCOC = m-hydroxycocaine; m-HOBZE = m-hydroxybenzoylecgonine; p-HOCOC = p-hydroxycocaine;/>HOBZE = p-hydroxybenzoylecgonine; SEM = standard error of the mean zoylecgonine. This unknown metabolite displayed fragment ions at m/z 240, 82, 256, and 94, which were in common with m-hydroxybenzoylecgonine and which suggested that this unidentified metabolite was o-hydroxybenzoylecgonine.
Measurement of cocaine and analytes in urine of female and male heavy cocaine users
Urine specimens from 17 female and 17 male cocaine users were selected for GC-MS analysis based on TDx measurements for cocaine metabolite (benzoylecgonine equivalents) that were greater than 100,000 ng/mL. These highly concentrated urine specimens were selected to facilitate the identification and measurement of minor cocaine metabolites. Concentrations of cocaine and 12 analytes by GC-MS for the 34 specimens are listed in Table lI . Among the analytes, mean benzoylecgonine concentrations were highest (range, 50,000-1,200,000 ng/mL), followed by ecgonine methyl ester (range, 400-500,000 ng/mL), cocaine (range, 0-100,000 ng/mL), and benzoylnorecgonine concentrations (range, 200-50,000 ng/mL). Norcocaine concentrations were consistently less than 10% of cocaine concentrations. Cocaethylene and its related metabolites, norcocaethylene and ecgonine ethyl ester, were detected in approximately half of the specimens in low to moderate concentrations. The m-and p-hydroxy-isomers of cocaine and benzoylecgonine were present in nearly all specimens in concentrations ranging from 60 to 50,000 ng/mL. No significant differences were present in cocaine analyte concentrations between women and men.
Measurement of cocaine and analytes in meconium of infants exposed to cocaine
Meconium specimens collected from six newborn infants of mothers who abused cocaine were analyzed by GC-MS for cocaine and 12 analytes. The results are shown in Table III . In most of the infants, benzoylecgonine (range, 53-6370 ng/g) and ecgonine methyl ester (range, 77-5672 ng/g) were highest in concentration, folJowed by cocaine (range, 44-1294 ng/g) and m-hydroxybenzoylecgonine concentrations (range, 48-1061 ng/g). Other metabolites measured in lower concentrations included anhydroecgonine methyl ester, ecgonine
Cross-reactivity of cocaine and analytes in EMIT and TDx cocaine metabolite assays
The m-and p-hydroxy-metabolites of benzoylecgonine displayed approximately equivalent cross-reactivities to benzoylecgonine in the EMIT and TDx assays for cocaine metabolite (Table IV) . p-Hydroxycocaine displayed approximately 14% cross-reactivity in the EMIT assay and cocaine, norcocaine, benzoylnorecgonine, and m-hydroxycocaine displayed 1-4%. The remainder of the analytes were nonreactive at the highest concentration tested (10,000 ng/mL).
Discussion
According to a 1993 National Pregnancy and Health Survey, the incidence of pregnant women in the general population who abuse cocaine was approximately 1.1% (21) . In high-risk urban populations, prevalence estimates have ranged as high as 44% (22) . Concurrent use of cocaine, ethanol, and other chemical substances is common among the child-bearing-age population of women who use cocaine. The use and abuse of drugs by a pregnant woman can result in adverse sequelae for the fetus antepartum, peripartum, and postpartum. Possible negative effects of intrauterine cocaine exposure include prematurity, low birth weight, low birth length, small head size, cerebral hemorrhage and infarction, fetal hypoxemia from uterine artery vasoconstriction, fetal hypertension, genitourinary defects, cardiovascular toxicity, respiratory problems, cognitive and developmental problems, abruptio placentae, sudden infant death syndrome, and miscarriage or stillbirth (22) (23) (24) (25) (26) (27) . Cocaine metabolites, hydrolysis products, and pyrolytic products, in addition to cocaine, have also been implicated as either causal or contributory in many of these processes (3, 17, 24, 28, 29) .
Meconium testing for cocaine has become a widely accepted method for determination of intrauterine drug exposure 9 Abbreviations: AEME = anhydroecgonine methyl ester; EME = ecgonine methyl ester; EEE = ecgonine ethyl ester; COC = cocaine; CE = cocaethylene; BZE = benzoylecgonine; NCOC = norcocaine; NCE = norcocaethylene; BNE = benzoylnorecgonine; m-HOCOC = m-hydroxycocaine; m-HOBZF = m-hydroxybenzoylecgonine; p-HOCOC = p-hydroxyc~caine; p-HO•ZE = p-hydroxybenzoylecgonine; gEM = standard error of the mean because of its improved sensitivity for fetal cocaine exposure as compared with urine testing (25, (30) (31) (32) (33) (34) . Meconium begins to form approximately 12-16 weeks after conception, and cocaine and metabolites may also begin to accumulate at this time. Ostrea et al. (35) reported the presence of cocaine in meconium by radioimmunoassay from a fetus that was spontaneously aborted at 17 weeks of gestation from a mother who admitted cocaine use during pregnancy. Concentrations of cocaine and benzoylecgonine appear to be highest in meconium specimens collected immediately after delivery and taper off 2-3 days postpartum (36) . Other cocaine metabolites have also been measured in meconium including ecgonine methyl ester, cocaethylene, norcocaine, benzoylnorecgonine, and m-hydroxybenzoylecgonine (15) (16) (17) 37, 38) . In the present study, additional new cocaine analytes identified in meconium were anhydroecgonine methyl ester, ecgonine ethyl ester, norcocaethylene, m-and p-hydroxycocaine, and p-hydroxybenzoylecgonine. Steele et al. (12) identified m-hydroxybenzoylecgonine in meconium specimens and reported that this metabolite accounted for a significant portion of the immunoreactivity for benzoylecgonine in meconium of fetuses exposed to cocaine. They reported the apparent cross-reactivity of m-hydroxybenzoylecgonine at 100 ng/mL to be 97% with EMIT and 150% with TDx. These estimates are in general agreement with those measured in the present experiment (Table IV) . The equivalent cross-reactivities of m-and p-hydroxybenzoylecgonine to benzoylecgonine indicate that these metabolites potentially play an important role in screening newborns for cocaine exposure. Additionally, in three of six meconium specimens examined in this study, the concentration of p-hydroxybenzoylecgonine was equal to or greater than m-hydroxybenzoylecgonine. Although the number of cases was limited, the data suggest that p-hydroxybenzoylecgonine may also contribute to Anhydroecgonine 0 (10,000 ng/mL) 0.7 (10,000 ng/mL) methyl ester Ecgonine methyl ester 0 (10,000 ng/mL) 0 (10,000 n 'g/mL) Ecgonine ethyl ester 0 (10,000 ng/mL) 0 (10,000 np-/mL) Cocaine 2.7 (10,000 ng/mL) 4.1 (10,000 ng/mL) Cocaethylene 1.1 (10,000 ng/mL) 1.2 (10,000 ng/mL) Benzoylecgonine 1033 (100 ng/mL) 82.2 (1000 ng/mL) Norcocaine 0.7 (10,000 ng/mL) (1.7 (10,000 ng/mL) Norcocaethylene 0 (10,000 ng/mL) 0.1 (10,000 ng/mL) Benzoylnorecgonine 1.4 (10,000 ng/mL) 0.7 (10,000 ng/mL) m-Hydroxycocaine 2.5 (1000 ng/mL) 0 (1000 ng/mL) rn-Hydroxybenzoylecgonine 89 (100 ng/mL) 95 (1000 ng/mL) p-Hydroxycocaine 13.7 (1000 ng/mL) 0.5 (1000 ng/mL) p-Hydroxybenzoylecgonine 113 (100 ng/mL) 108 (1000 ng/mL) *Apparent cross-reactivity was determined as the ratio of apparent concentration/ target drug concentration x ! 00. The concentration at which cross-reactivity was measured is shown in parentheses.
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Journal of Analytical Toxicology, Vol. 20, October 1996 unconfirmed positive immunoassay results. As with m-hydroxybenzoylecgonine (13), monitoring of p-hydroxybenzoylecgonine by GC-MS, in addition to cocaine and benzoylecgonine, could lead to an increased confirmation rate. Early identification and treatment of neonates exposed to cocaine could lead to fewer long-term sequelae and a better understanding of the effects of fetal cocaine exposure. Many chemical and metabolic changes that occur during cocaine administration are processes that are particular to specific actions, enzymatic processes, and body sites. Consequently, an examination of the metabolic profile of cocaine in different body fluids can be highly revealing. For example, anhydroecgonine methyl ester is generally considered to be a marker for smoked "crack" cocaine because it is produced by heat during vaporization. Its presence in meconium would appear to indicate that these mothers smoked "crack" cocaine during pregnancy. In addition, the presence of cocaethylene and its metabolites, norcocaethylene and ecgonine ethyl ester, in meconium is indicative of maternal coadministration of cocaine and ethanol during the last two trimesters of pregnancy. Cocaethylene is formed via an enzyme-mediated transesterification of cocaine and ethanol by carboxylesterases located in the liver and kidney (39) . Cocaethylene appears to produce cardiovascular effects that are similar to those produced by cocaine (3); however, increased lethality has been reported for cocaethylene compared with cocaine (40, 41) . Identification of cocaethylene in meconium may also lead to the identification of neonates at risk for fetal alcohol syndrome. The presence of norcocaine and the m-and p-hydroxy-isomers of cocaine and benzoylecgonine indicates that cocaine was metabolized by oxidative enzymes located primarily in the liver.
The origin of cocaine metabolites in meconium is difficult to determine. Of the 13 cocaine analytes that were detected, only cocaine and anhydroecgonine methyl ester can confidently be traced to the mother. Reports of m-hydroxybenzoylecgonine in meconium (12, 13) suggested that this metabolite could be formed primarily by the fetus. The present study examined urine specimens from adult cocaine users to determine if m-hydroxybenzoylecgonine and related hydroxy-metabolites were produced by adult women, p-Hydroxybenzoylecgonine was more abundant in adult urine than the m-isomer by an approximate 5:1 ratio. However, this ratio was highly variable and was not consistent in meconium, m-Hydroxycocaine and p-hydroxycocaine were generally present in smaller amounts than the hydroxybenzoylecgonine isomers in both urine and meconium. The presence of the hydroxy-metabolites in urine specimens of adult female cocaine users indicates the possibility that their presence in meconium could be due to transfer across the placenta from the pregnant mother to the developing fetus. Further studies with animal models will be necessary to differentiate the source of these unusual metabolites in meconium.
Quantitation of cocaine analytes in urine specimens of female and male adults that were identified as heavy cocaine users revealed no significant differences in the overall pattern of metabolism (Table II) . Female and male cocaine users excreted m-and p-hydroxybenzoylecgonine in approximately equal amounts; hence, there were no sex-related differences in the excretion of these metabolites. Benzoylecgonine concentrations ranged from 30,000 to 1,200,000 ng/mL for the 34 subjects. For comparison, administration of 42 mg of cocaine base by the smoked route of administration produced average maximum concentrations of benzoylecgonine for four subjects of 6000 (• ng/mL at a peak excretion time of approximately 8 h (unpublished data). This suggests that the amount of cocaine used by heavy cocaine users in the current study was a minimum of 5-200 times more than that administered in the controlled dosing study. Cocaine was present in 31 of 34 of the heavy users' specimens, which indicated that recent use had occurred. The presence of cocaethylene and its related metabolites, ecgonine ethyl ester and norcocaethylene, indicated that seven women and nine men had also ingested ethanol recently. The average concentration (plus or minus standard error of the mean) of cocaethylene in the positive specimens from women (1852 • 667 ng/mL) tended to be higher than that observed in men (52 • 10 ng/mL), although the overall concentrations were not significantly different. Five of seven women who tested positive for cocaethylene were diagnosed as being currently dependent on alcohol (42) , whereas only two of nine men were currently dependent (Table I) . Also, two of the women and none of the men positive for cocaethylene had a positive breath alcohol test (cutoff, greater than 0.005 g/dL) on the day of the specimen collection. In addition, four of the women reported heavy alcohol use (10-30 days of use in the past 30 days), whereas only one of the men positive for cocaethylene reported heavy alcohol use. Anhydroecgonine methyl ester was present in 29 of 34 urine specimens, although only four subjects reported that the smoked route was the preferred route of administration of cocaine. Because most of the subjects were recent or current intravenous heroin users as well as being dependent on cocaine, it is likely that they frequently used both routes for cocaine administration.
In summary, the data from the present study demonstrated that the source of cocaine analytes in meconium of fetuses exposed to cocaine in utero, whether fetal or maternal, is still undetermined. The presence of cocaine and its pyrolysis product, anhydroecgonine methyl ester, in meconium could be attributed to transport from the mother across the placenta; however, the source of other hydrolytic and oxidative metabolites could not be established. Substantial amounts of these metabolites were identified in urine from adult cocaine users and in meconium. Consequently, the hydroxy-isomers of benzoylecgonine and cocaine are not unique fetal metabolites of cocaine but can serve as additional markers of cocaine exposure in meconium specimens from newborn infants.
